Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for Neutropenia Prophylaxis After Chemotherapy
NCT02905916Phase 4Unknown
- Sponsor
- Peking University
- Start
- Jun 2016
- Primary completion
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegfilgrastim in neutropenia, sponsored by Peking University. Primary endpoint: Incidence of febrile neutropenia at 30 days. Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02905916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905916.